Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Cox

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|April 20, 2016
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101Ramamoorthy Nagasubramanian, Julie Wei, Paul Gordon, et al.
Current Drug Metabolism|August 22, 2006
Thalidomide metabolism and hydrolysis: mechanisms and implicationsErin R Lepper, Nicola F Smith, Michael C Cox, et al.
Pediatric Blood & Cancer|June 13, 2018
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephromaHadeel Halalsheh, Mary Beth McCarville, Michael Neel, et al.
Cancer Biology & Therapy|March 19, 2003
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomideYuichi Ando, Douglas K Price, William L Dahut, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Cancer|December 8, 2005
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinomaFlora Rozhansky, Ming-Hui Chen, Michael C Cox, et al.
Blood Advances|November 15, 2019
Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemiaDenis M Schewe, Lennart Lenk, Fotini Vogiatzi, et al.
World Journal of Urology|December 14, 2004
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancerWilliam D Figg, Michael E Franks, David Venzon, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
JCO Precision Oncology|July 6, 2023
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel <i>SNX8-BRAF</i> Gene FusionKatharine Offer, Michael T McGuire, Kunchang Song, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|April 20, 2016
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101Ramamoorthy Nagasubramanian, Julie Wei, Paul Gordon, et al.
Current Drug Metabolism|August 22, 2006
Thalidomide metabolism and hydrolysis: mechanisms and implicationsErin R Lepper, Nicola F Smith, Michael C Cox, et al.
Pediatric Blood & Cancer|June 13, 2018
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephromaHadeel Halalsheh, Mary Beth McCarville, Michael Neel, et al.
Cancer Biology & Therapy|March 19, 2003
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomideYuichi Ando, Douglas K Price, William L Dahut, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Cancer|December 8, 2005
Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinomaFlora Rozhansky, Ming-Hui Chen, Michael C Cox, et al.
Blood Advances|November 15, 2019
Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemiaDenis M Schewe, Lennart Lenk, Fotini Vogiatzi, et al.
World Journal of Urology|December 14, 2004
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancerWilliam D Figg, Michael E Franks, David Venzon, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
JCO Precision Oncology|July 6, 2023
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel <i>SNX8-BRAF</i> Gene FusionKatharine Offer, Michael T McGuire, Kunchang Song, et al.
Pageof 5